Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

YOU WONT BELIEVE: Novo nordisk | Mind Blowing Facts

Women with PMOS should get subsidised weight-loss drugs, Australian advocates say

With GLP-1s to treat the condition not specifically approved by the TGA, patients are being prescribed them off-label

The Guardian - AU · Oct 9

Ozempic and Zepbound Makers Report Slower Aging Clocks, but Unreviewed Data Do Not Prove Patients Age Slower

Novo Nordisk and Eli Lilly say GLP-1 drugs slowed aging clocks, but the data are early and unreviewed. Here is what patients should know.

Medical Daily · Oct 8

Novo Nordisk’s CEO Was Asked Why His Stock Keeps Falling on Good News: ‘The Stock Market Is Always Right, but With a Bit of a Time Difference’

Investors say Novo Nordisk's results are among the best ever. Here's what their CEO says about why the stock price hasn't caught up yet.

Barchart · Oct 8

From analysis to the latest developments in health,
read the most diverse news in one place.

Manufacturing Site Problems, Not Trial Results, Push Back FDA Decision on Novo's Once-Monthly Hemophilia A Drug Denecimig

FDA's review of Novo's hemophilia A drug denecimig is delayed by manufacturing site issues, not trial data. Launch is now targeted for 2027.

Medical Daily · Oct 5

NVO vs. LLY: Novo’s CEO Says Confidence Is Gone. Lilly Is Winning 7 in 10 New Seniors.

Eli Lilly continues to outpace Novo Nordisk in the weight-loss market, supported by stronger patient growth and market share gains.

Barchart · Oct 5

Postpartum GLP-1 Prescriptions Rose Nearly 24-Fold Among Privately Insured New Mothers, with Breastfeeding Safety Data Still Limited

A JAMA study of 1 million births found postpartum GLP-1 prescriptions rose nearly 24-fold. What new mothers should know about breastfeeding and cost.

Medical Daily · Oct 4

Liver Fat Fell to Normal in 23 of 26 Adults with Obesity in Small Wegovy Post Hoc Analysis

In a small Novo Nordisk analysis, 23 of 26 adults with obesity and excess liver fat reached normal levels on semaglutide. Here is what the numbers do and do not show.

Medical Daily · Oct 3

Read news from The Economist, FT, and more,
with one subscription

Participants Taking CagriSema Showed Changed Brain Responses to High-Calorie Food Images in Novo Study as FDA Decision Nears

Novo says brain scans showed CagriSema changed food-cue responses and cut cravings. The data are early, and an FDA decision is expected in late 2026.

Medical Daily · Oct 2

Counterfeit Ozempic Charges Allege a China Supply Pipeline as Patients Are Urged to Check Pens and Verify Pharmacies

Federal charges allege that fake Ozempic from China reached U.S. distributors. Learn how to spot counterfeit pens and verify a pharmacy's license.

Medical Daily · Oct 2

Novo Nordisk Licenses Experimental Once-Weekly Obesity Pill From China's Hengrui in Deal Worth Up to $2.6 Billion

Novo Nordisk will pay $300 million upfront, and up to $2.6 billion in total, for Hengrui's once-weekly GLP-1/GIP pill, which has not been tested in people.

Medical Daily · Oct 1

Foundayo Pill Edged Higher-Dose Oral Semaglutide on Weight and A1C in Lilly's Indirect Type 2 Diabetes Analysis

Lilly's indirect analysis found Foundayo 17.2 mg edged oral semaglutide 25 mg on weight and A1C in type 2 diabetes, but the gaps were modest.

Medical Daily · Oct 1

If You Love Speculating, You Should Keep a Close Eye on Novo Nordisk Stock

Yes, NVO is a stinker but powerhouse names caught in a bearish wind tend to enjoy transitional swings.

Barchart · Sep 30

Novo-Funded Analysis Ties Raising Ozempic to 2 mg to Slightly Lower Heart Risk Than Switching to Mounjaro

A Novo-funded claims analysis tied raising Ozempic to 2 mg with 6% lower heart risk than switching to Mounjaro. Here is why confounding matters.

Medical Daily · Sep 30

Ozempic Users Worried About Pancreatic Cancer Get Reassuring Nordic Registry Data, but Follow-Up Lasted Under Two Years

A Novo-funded Nordic study of 97,464 semaglutide users found no rise in pancreatic cancer, but follow-up lasted under two years after a lag.

Medical Daily · Sep 30

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily · Sep 30

Novo Nordisk Increasingly Calls Wegovy Users Customers, Months After FDA Flagged a 'Live Lighter' Pill Ad Claim

STAT reports Novo now markets Wegovy to customers, months after the FDA called a Wegovy pill ad misleading. What cash-pay buyers should check first.

Medical Daily · Sep 29

Wegovy Users with Heart Disease May Get Protection Beyond Weight Loss, but Researchers Still Cannot Explain Why

A new SELECT analysis finds Wegovy's heart benefit is not fully explained by weight loss or other known risk factors. Here is what it means for patients.

Medical Daily · Sep 28

Retatrutide Diabetes Results, Mounjaro Heart Data, and Wegovy Pill Switching Study Lead EASD 2026 Meeting Opening in Milan

EASD 2026 opens in Milan with retatrutide, Mounjaro heart, and Wegovy pill data due this week. Here is the schedule and what the numbers show.

International Business Times · Sep 25

Nanexa Stock Skyrockets More Than 100% After Signing Drug Deal With Wegovy Maker Novo Nordisk

Under the deal, Novo gets the right to use PharmaShell in as many as five development programs for peptide-based medicines targeting obesity, type 2 diabetes and other cardiometabolic diseases.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart · Sep 25

Novo Nordisk Changed the World With Its GLP-1 Weight-Loss Drugs. Now It Wants to Help Cure Baldness.

The Danish pharmaceutical giant that brought the world Ozempic may be ready to start researching a cure for hair loss. From a business perspective, it's a smart move.

Medical Daily · Sep 25

Florida Sues Insulin Makers and Drug Middlemen, Alleging Pricing Deals Raised Costs for Residents Who Rely on Insulin

Florida's attorney general alleges insulin makers and PBMs inflated the list prices that many patients pay. What the lawsuit claims and how to cut costs.

The Economic Times · Sep 24

GLP-1 users are suing over vision loss: What does the evidence really show?

Dozens of patients have taken legal action against drug manufacturers, filing personal injury lawsuits that allege they were not adequately warned about the risk of a rare type of sudden vision loss, ABC News reported.

Medical Daily · Sep 24

Hundreds of Lawsuits Allege Ozempic and Other GLP-1 Drugs Caused Sudden Vision Loss, but Absolute Risk Appears Low

Hundreds of lawsuits claim Ozempic and other GLP-1 drugs caused sudden vision loss. What the evidence shows, who faces the most risk, and symptoms to know.

International Business Times UK · Sep 24

700,000 Seniors Start GLP-1 Weight-Loss Drugs — but US Taxpayers Cover $195 Per Patient

Eli Lilly says 700,000 US seniors started GLP-1 treatment through Medicare's Bridge scheme, with taxpayers covering about $195 per patient each month.

MarketBeat · Sep 23

Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?

Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.

Medical Daily · Sep 23

Self-Pay Channels Make Up Half of Wegovy Business and 90% of Pill Demand as Families Weigh Cash Prices

Novo Nordisk says self-pay channels now make up half of its Wegovy business. Here is what cash prices cost families and which coverage options remain.

1 2 3 4 5

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.